JP2018514226A5 - - Google Patents

Download PDF

Info

Publication number
JP2018514226A5
JP2018514226A5 JP2018502328A JP2018502328A JP2018514226A5 JP 2018514226 A5 JP2018514226 A5 JP 2018514226A5 JP 2018502328 A JP2018502328 A JP 2018502328A JP 2018502328 A JP2018502328 A JP 2018502328A JP 2018514226 A5 JP2018514226 A5 JP 2018514226A5
Authority
JP
Japan
Prior art keywords
sequence identity
seq
configuration
polypeptide according
residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018502328A
Other languages
English (en)
Japanese (ja)
Other versions
JP6895421B2 (ja
JP2018514226A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/057021 external-priority patent/WO2016156465A1/en
Publication of JP2018514226A publication Critical patent/JP2018514226A/ja
Publication of JP2018514226A5 publication Critical patent/JP2018514226A5/ja
Application granted granted Critical
Publication of JP6895421B2 publication Critical patent/JP6895421B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018502328A 2015-03-31 2016-03-31 ポリペプチド Active JP6895421B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15162112.5 2015-03-31
EP15162112 2015-03-31
PCT/EP2016/057021 WO2016156465A1 (en) 2015-03-31 2016-03-31 Polypeptides

Publications (3)

Publication Number Publication Date
JP2018514226A JP2018514226A (ja) 2018-06-07
JP2018514226A5 true JP2018514226A5 (https=) 2019-05-16
JP6895421B2 JP6895421B2 (ja) 2021-06-30

Family

ID=52811024

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018502328A Active JP6895421B2 (ja) 2015-03-31 2016-03-31 ポリペプチド

Country Status (14)

Country Link
US (3) US10633438B2 (https=)
EP (2) EP4089113B1 (https=)
JP (1) JP6895421B2 (https=)
KR (1) KR102622281B1 (https=)
CN (1) CN107454905B (https=)
AU (1) AU2016239948B2 (https=)
CA (2) CA3255406A1 (https=)
DK (2) DK4089113T3 (https=)
EA (1) EA035638B1 (https=)
ES (2) ES2973042T3 (https=)
IL (1) IL254577B2 (https=)
MX (1) MX2017012662A (https=)
SG (1) SG11201706839YA (https=)
WO (1) WO2016156465A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8188223B2 (en) * 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
CA3255406A1 (en) * 2015-03-31 2025-07-03 Sorriso Pharmaceuticals, Inc. Tnf-alpha binding polypeptides
SG11201706840WA (en) 2015-03-31 2017-09-28 Vhsquared Ltd Peptide construct having a protease-cleavable linker
EP3405491A1 (en) 2016-01-21 2018-11-28 VHsquared Limited Polypeptides
SG11201807402PA (en) * 2016-03-31 2018-09-27 Vhsquared Ltd Compositions
EP3519438A1 (en) * 2016-09-30 2019-08-07 VHsquared Limited Compositions
CN117045784A (zh) 2016-12-14 2023-11-14 比奥拉治疗股份有限公司 使用利用可摄入装置释放的il-12/il-23抑制剂治疗胃肠道疾病
CN110430801B (zh) 2016-12-14 2024-04-30 比奥拉治疗股份有限公司 使用tnf抑制剂治疗胃肠道疾病
EP3581203A1 (en) * 2018-06-11 2019-12-18 Laboratoire Français du Fractionnement et des Biotechnologies Antibodies with increased activity in the digestive tract
US20230312700A1 (en) 2018-06-20 2023-10-05 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
EP3853612A4 (en) * 2018-09-18 2021-10-27 Siemens Healthcare Diagnostics, Inc. PROCEDURES AND REAGENTS FOR CIKAVIRUS IMMUNOASSAYS
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
WO2020144164A1 (en) 2019-01-07 2020-07-16 Bactolife Aps Pathogen binding proteins
CN111499762B (zh) * 2019-01-31 2022-04-26 四川大学华西医院 一种包含PDGFRβ特异性亲和体和TNFα的融合蛋白及其用途
JP7778567B2 (ja) * 2019-04-17 2025-12-02 ミレニアム ファーマシューティカルズ, インコーポレイテッド α4β7阻害薬及びIL-23阻害薬の併用療法
CN120210127A (zh) 2019-05-31 2025-06-27 塔夫茨大学信托人 使用基因修饰细胞的培养肉产品
KR20220063148A (ko) 2019-06-21 2022-05-17 소리소 파마슈티컬스 인크. 조성물
US12559552B2 (en) 2019-06-21 2026-02-24 Sorriso Pharmaceuticals, Inc. IL-23 and TNF-alpha binding bi-specific heavy chain polypeptides
CA3144567A1 (en) * 2019-06-21 2020-12-24 Scott Crowe Polypeptides
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
CN120019080A (zh) * 2022-08-09 2025-05-16 普腾泰科集团有限公司 用于抗体标记的多价接头
EP4630451A2 (en) * 2022-12-05 2025-10-15 Fzata, Inc. Oral treatments for pain comprising tnf-alpha binding proteins
WO2025090840A1 (en) * 2023-10-27 2025-05-01 Rutgers, The State University Of New Jersey Antigen binding molecules targeting tnf-alpha

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3443119B2 (ja) 1989-08-07 2003-09-02 ペプテック リミテッド 腫瘍壊死因子結合リガンド
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
DK1027439T3 (da) 1997-10-27 2010-05-10 Bac Ip Bv Multivalente antigenbindende proteiner
EP0954978B1 (en) 1998-03-12 2011-11-30 VHsquared Limited New products comprising inactivated yeasts or moulds provided with active antibodies
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
CZ303983B6 (cs) 2000-12-13 2013-07-31 Unilever N. V. Zpusob výroby heterologního proteinu
CA2450793A1 (en) * 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
WO2004009776A2 (en) 2002-07-19 2004-01-29 Abbott Biotechnology Ltd. TREATMENT OF TNFα RELATED DISORDERS
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
WO2004041863A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
EP1558645B1 (en) 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
US20060034845A1 (en) * 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US20060034833A1 (en) 2002-11-08 2006-02-16 Els Beirnaert Single domain antibodies directed against interferron-gamma and uses therefor
EP1900753B1 (en) 2002-11-08 2017-08-09 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
TW201705980A (zh) 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療TNFα相關失調症之多重可變劑量療法
CN101039959A (zh) * 2004-06-30 2007-09-19 杜门蒂斯有限公司 用于治疗炎性疾病的组合物和方法
US8188223B2 (en) 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
US20070042399A1 (en) 2005-06-23 2007-02-22 Imperial College Innovations Limited Biological materials and uses thereof
ES2626610T3 (es) 2005-08-30 2017-07-25 Intrexon Actobiotics Nv Bacterias de ácido láctico productoras del anti-TNF alfa para el tratamiento de la enfermedad inflamatoria intestinal
WO2007048022A2 (en) 2005-10-21 2007-04-26 Alexion Pharmaceuticals, Inc. Antibody-polypeptide fusion proteins and methods for producing and using same
AU2006326867A1 (en) 2005-12-20 2007-06-28 Cephalon Australia Pty Ltd Chimeric antibodies with part New World primate binding regions
US20110059101A9 (en) 2006-03-13 2011-03-10 Ablynx N.V. Amino Acid Sequences Directed Against Il-6 And Polypetides Comprising The Same For The Treatment Of Diseases And Disorders Associated With Il-6 Mediated Signalling
WO2008042067A2 (en) 2006-09-28 2008-04-10 Illumina, Inc. Compositions and methods for nucleotide sequencing
CA2667466A1 (en) 2006-10-27 2008-05-02 Ablynx N.V. Intranasal delivery of polypeptides and proteins
US20160031971A9 (en) 2007-02-20 2016-02-04 Tufts University Methods and compositions with a recombinant neutralizing binding protein for treating toxin exposure
EP2121757A2 (en) 2007-02-21 2009-11-25 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
US7807168B2 (en) 2007-04-10 2010-10-05 Vaccinex, Inc. Selection of human TNFα specific antibodies
TW201531484A (zh) 2007-05-21 2015-08-16 Alder Biopharmaceuticals Inc 抗TNF-α之抗體及其用途
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
CA2696263C (en) 2007-08-15 2017-06-13 Bing Liu Monospecific and multispecific antibodies and method of use
EP2725035A1 (en) 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
EP2650311A3 (en) 2007-11-27 2014-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
LT2285408T (lt) 2008-06-05 2019-01-25 Ablynx N.V. Aminorūgščių sekos, nukreiptos prieš viruso apvalkalo baltymus, ir tokias sekas turintys polipeptidai, skirti virusinių ligų gydymui
GB0815264D0 (en) 2008-08-21 2008-09-24 Syntaxin Ltd Non-cytotoxic proteins
WO2010045506A2 (en) 2008-10-16 2010-04-22 Kathleen Cogan Farinas Sustained drug delivery system
BRPI0919879A2 (pt) 2008-10-29 2016-02-16 Wyeth Llc métodos para purificação de moléculas de ligação a antígeno de domínio único
CA2738243C (en) 2008-10-29 2020-09-29 Wyeth Llc Formulations of single domain antigen binding molecules
CL2010000019A1 (es) 2010-01-11 2010-06-11 Univ Chile Anticuerpo monoclonal contra el tnf humano y sus fragmentos, secuencias nucleotidicas que lo codifican, vector de expresion y celulas que las contienen, composiciones y kit que comprenden el anticuerpo, uso de los mismos y metodo para su obtencion.
WO2011139629A2 (en) 2010-04-26 2011-11-10 Biogen Idec Ma Inc. Light targeting molecules and uses thereof
WO2011135040A1 (en) 2010-04-30 2011-11-03 F. Hoffmann-La Roche Ag Fluorescent antibody fusion protein, its production and use
CN103119062A (zh) 2010-07-16 2013-05-22 埃博灵克斯股份有限公司 修饰的单结构域抗原结合分子及其应用
EP2632949B1 (en) * 2010-10-25 2017-09-13 National Research Council of Canada Clostridium difficile-specific antibodies and uses thereof
AR084210A1 (es) 2010-12-08 2013-05-02 Abbott Lab PROTEINAS DE UNION AL TNF-a
MX361242B (es) 2011-03-30 2018-11-30 Ablynx Nv Anticuerpos de dominio sencillo contra tnf-alfa y usos de los mismos.
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
SG10201805064SA (en) 2011-06-23 2018-07-30 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
PE20141522A1 (es) 2011-08-17 2014-11-17 Glaxo Group Ltd Proteinas y peptidos modificados
KR20140084201A (ko) 2011-10-19 2014-07-04 알렉시온 파마 홀딩 알칼리성 포스파타제 및/또는 나트륨이뇨 펩티드를 포함하는 조성물 및 그의 사용 방법
GB2504139B (en) 2012-07-20 2014-12-31 Argen X Bv Antibodies to highly conserved targets produced by the immunisation of Camelidae species
DE102011121238A1 (de) 2011-12-14 2013-06-20 Universitätsklinikum Hamburg-Eppendorf Einzeldomänen-antikörper gegen clostridium difficile toxine
DE102011121237A1 (de) 2011-12-14 2013-06-20 Universitätsklinikum Hamburg-Eppendorf Einzeldomänen-Antikörper gegen Clostridium difficile Toxin CDTa
US9879093B2 (en) 2011-12-20 2018-01-30 Adaerata, Limited Partnershp Single domain antibodies as inhibitors of PCSK9
CA2875783C (en) 2012-06-06 2018-12-11 Zoetis Llc Caninized anti-ngf antibodies and methods thereof
US9540449B2 (en) 2012-08-13 2017-01-10 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 antibodies with pH-dependent binding characteristics
US20140186365A1 (en) 2013-01-03 2014-07-03 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Antibodies that specifically bind to serum albumin without interfering with albumin's capability to interact with the fcrn
US9416197B2 (en) 2013-11-01 2016-08-16 Ibc Pharmaceuticals, Inc. Bispecific antibodies that neutralize both TNF-α and IL-6: novel therapeutic agent for autoimmune disease
WO2015100409A2 (en) 2013-12-26 2015-07-02 Tufts University Methods, compositions and kits for treating a subject using a recombinant neutralizing binding protein
JP6832707B2 (ja) 2014-03-26 2021-02-24 セル メディカ スイッツァランド アーゲー TNFαに対する結合メンバー
US20160115247A1 (en) 2014-10-23 2016-04-28 Singh Biotechnology, Llc Single domain antibodies directed against intracellular antigens
EP3237000A1 (en) 2014-12-23 2017-11-01 Pfizer Inc Stable aqueous antibody formulation for anti tnf alpha antibodies
WO2016156474A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptide comprising an immunoglobulin chain variable domain which binds to clostridium difficile toxin a
SG11201706840WA (en) 2015-03-31 2017-09-28 Vhsquared Ltd Peptide construct having a protease-cleavable linker
CA3255406A1 (en) 2015-03-31 2025-07-03 Sorriso Pharmaceuticals, Inc. Tnf-alpha binding polypeptides
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
EP3277706A1 (en) 2015-03-31 2018-02-07 VHsquared Limited Polypeptide comprising an immunoglobulin chain variable domain which binds to clostridium difficile toxin b
EP3078675A1 (en) 2015-04-10 2016-10-12 Ares Trading S.A. Induction dosing regimen for the treatment of tnf alpha mediated disorders
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
EP3405491A1 (en) 2016-01-21 2018-11-28 VHsquared Limited Polypeptides
SG11201807402PA (en) 2016-03-31 2018-09-27 Vhsquared Ltd Compositions
EP3519438A1 (en) 2016-09-30 2019-08-07 VHsquared Limited Compositions

Similar Documents

Publication Publication Date Title
JP2018514226A5 (https=)
EP4067377A1 (en) Development and application of therapeutic agents for tslp-related diseases
CN104774266B (zh) 白介素-13结合蛋白
CN108473563B (zh) 改进的tnf结合剂
JP2022538083A5 (https=)
JP2022537780A5 (https=)
JP2014513953A5 (https=)
JP2022538089A5 (https=)
WO2015006736A2 (en) Coiled coil immunoglobulin fusion proteins and compositions thereof
JP2023505492A5 (https=)
CN102369217A (zh) Il-1结合蛋白
JP2018511346A5 (https=)
CN108473568A (zh) 对TNF-α、IL-17A和IL-17F具有特异性的多特异性抗体分子
JP2011518857A5 (https=)
JP2022538232A5 (https=)
JP2017523805A5 (https=)
NZ734798B2 (en) Polypeptides
WO2021194985A1 (en) Anti-sars-cov-2 antibodies derived from 6nb6
EP2909235B1 (en) Polypeptides specifically binding to il-23
CN118019760A (zh) 抗IL-1-β抗体
RU2774823C2 (ru) Усовершенствованные агенты, связывающие tnf
JP2024534717A (ja) 中等症から重症のアトピー性皮膚炎の処置のための方法
CA2376882A1 (en) Novel recombinant antibody, amino acid sequences of its complementarity determining regions and genes encoding the same
NZ770866B2 (en) Anti-human tlr7 antibody
TH2001003244A (th) แอนติบอดีที่จับกับ lilrb2